{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:20:17Z","timestamp":1791958817185,"version":"4.3.4"},"update-to":[{"DOI":"10.1371\/journal.pntd.0011443","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000}}],"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["U01FD006603"],"award-info":[{"award-number":["U01FD006603"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Between January and March 2022, WHO conducted a global online survey to collect data on diagnostic capacities and treatment practices in different settings for four implantation mycoses: eumycetoma, actinomycetoma, cutaneous sporotrichosis and chromoblastomycosis. The survey investigated the type of diagnostic methods available in countries at various health system levels (tertiary, secondary, primary level) and the medicines used to treat implantation mycoses, with a view to understanding the level of drug repurposing for treatment of these diseases. 142 respondents from 47 countries, including all continents, contributed data: 60% were from middle-income countries, with 59% working at the tertiary level of the health system and 30% at the secondary level. The results presented in this article provide information on the current diagnostic capacity and treatment trends for both pharmacological and non-pharmacological interventions. In addition, the survey provides insight on refractory case rates, as well as other challenges, such as availability and affordability of medicines, especially in middle-income countries. Although the study has limitations, the survey-collected data confirms that drug repurposing is occurring for all four surveyed implantation mycoses. The implementation of an openly accessible global and\/or a national treatment registry for implantation mycoses could contribute to address the gaps in epidemiological information and collect valuable observational data to inform treatment guidelines and clinical research.<\/jats:p>","DOI":"10.1371\/journal.pntd.0011443","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T17:36:18Z","timestamp":1687973778000},"page":"e0011443","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["Diagnostic capacities and treatment practices on implantation mycoses: Results from the 2022 WHO global online survey"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1145-4628","authenticated-orcid":true,"given":"Barbara","family":"Milani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Argaw","family":"Dagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Lynn","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Schito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather Anne","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,6,28]]},"reference":[{"key":"pntd.0011443.ref001","unstructured":"CURE ID: investigating drug repurposing opportunities to treat challenging infections [platform website(internet] [Cited 16 May 2023]. https:\/\/cure.ncats.io\/"},{"key":"pntd.0011443.ref002","unstructured":"CURE ID App Lets Clinicians Report Novel Uses of Existing Drugs, United States Food and Drug Administration, 6 June 2020 [Press release] [Cited 16 May 2023]. https:\/\/www.fda.gov\/drugs\/science-and-research-drugs\/cure-id-app-lets-clinicians-report-novel-uses-existing-drugs"},{"key":"pntd.0011443.ref003","unstructured":"Resolution WHA69.21. Addressing the burden of mycetoma, Geneva, World Health Organization, 2016 [Cited 16 May 2023]. https:\/\/apps.who.int\/iris\/handle\/10665\/252801"},{"key":"pntd.0011443.ref004","unstructured":"Tenth report of the Strategic and Technical Advisory Group for Neglected Tropical Diseases, Geneva, World Health Organization, 1 April 2017 [Cited 16 May 2023]. https:\/\/www.who.int\/publications\/m\/item\/tenth-report-of-the-strategic-and-technical-advisory-group-for-neglected-tropical-diseases-(stag-ntds))"},{"key":"pntd.0011443.ref005","unstructured":"Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021\u20132030, Geneva, World Health Organization, 2020 [Cited 16 May 2023]. https:\/\/apps.who.int\/iris\/handle\/10665\/338565"},{"issue":"6","key":"pntd.0011443.ref006","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/17460441.2022.2080195","article-title":"Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach","volume":"17","author":"W Lim","year":"2022","journal-title":"Expert Opin Drug Discov"},{"key":"pntd.0011443.ref007","unstructured":"Ending the neglect to attain the sustainable development goals: a strategic framework for integrated control and management of skin-related neglected tropical diseases, Geneva, World Health Organization; 2022 [Cited 16 May 2023]. https:\/\/apps.who.int\/iris\/handle\/10665\/355448"},{"issue":"4","key":"pntd.0011443.ref008","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/tropicalmed4040122","article-title":"The Diagnosis of Fungal Neglected Tropical Diseases (Fungal NTDs) and the Role of Investigation and Laboratory Tests: An Expert Consensus Report","volume":"4","author":"R Hay","year":"2019","journal-title":"Trop Med Infect Dis"},{"key":"pntd.0011443.ref009","unstructured":"Chromoblastomycosis, sporotrichosis & mycetoma: a WHO survey of global practices of diagnosis and drug treatments for subcutaneous mycoses [webinar launch\/internet]. London: International Society for Neglected Tropical Diseases; 17 February 2022 [Cited 16 May 2023]. https:\/\/www.youtube.com\/watch?v=aKhmkWbvp_4"},{"key":"pntd.0011443.ref010","unstructured":"Meeting report: The Use of Essential Drugs (1999), WHO Technical Report Series, No. 895, Geneva, World Health Organization, 2000 [Cited 16 May 2023]. https:\/\/www.who.int\/publications\/i\/item\/9241208953"},{"key":"pntd.0011443.ref011","unstructured":"WHO Drug Information Vol 22, No. 2, Geneva, World Health Organization, 2008 [Cited 16 May 2023]. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/74267\/22_2_2008.pdf?sequence=1&isAllowed=y"},{"key":"pntd.0011443.ref012","unstructured":"European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole, European Medicines Agency, 26\/07\/2013 [Press release] [Cited 16 May 2023]. https:\/\/www.ema.europa.eu\/en\/news\/european-medicines-agency-recommends-suspension-marketing-authorisations-oral-ketoconazole"},{"key":"pntd.0011443.ref013","unstructured":"FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems, Safety Announcement, United States Food and Drug Administration, 26\/7\/2013 [FDA Drug Safety Communication] [Cited 16 May 2023]. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-limits-usage-nizoral-ketoconazole-oral-tablets-due-potentially"},{"issue":"7","key":"pntd.0011443.ref014","first-page":"CD013082","article-title":"Drug therapy for Mycetoma","volume":"2018","author":"P Scolding","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"pntd.0011443.ref015","doi-asserted-by":"crossref","first-page":"e0008123","DOI":"10.1371\/journal.pntd.0008123","article-title":"Clinical characteristics and treatment of actinomycetoma in northeast Mexico: A case series","volume":"14","author":"J C\u00e1rdenas-de la Garza","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011443.ref016","first-page":"423","article-title":"Results of the 2017 global WHO survey on mycetoma","volume":"93","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"pntd.0011443.ref017","unstructured":"Proof-of-concept superiority trial of fosravuconazole versus itraconazole for eumycetoma in Sudan [ID trial: NCT03086226], World Health Organization International Clinical Trials Registry Platform [Cited 16 May 2023]. https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NCT03086226"},{"key":"pntd.0011443.ref018","unstructured":"Treatment of chromoblastomycosis with ALA-PDT. [ID study: ChiCTR1900023978], World Health Organization International Clinical Trials Registry Platform [Cited 16 May 2023]. https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR1900023978"},{"issue":"2","key":"pntd.0011443.ref019","doi-asserted-by":"crossref","first-page":"e0010159","DOI":"10.1371\/journal.pntd.0010159","article-title":"Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma","volume":"16","author":"W Lim","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pntd.0011443.ref020","doi-asserted-by":"crossref","first-page":"e0229630","DOI":"10.1371\/journal.pone.0229630","article-title":"A screening of the MMV Pathogen Box reveals new potential antifungal drugs against the etiologic agents of chromoblastomycosis","volume":"15","author":"R Coelho","year":"2020","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"pntd.0011443.ref021","article-title":"S4.5a A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan\u2014top line results","volume":"60","author":"A Fahal","year":"2022","journal-title":"Med Mycol"},{"issue":"10","key":"pntd.0011443.ref022","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3390\/jof8101004","article-title":"Screening of Pandemic Response Box Library Reveals the High Activity of Olorofim against Pathogenic Sporothrix Species","volume":"8","author":"L Borba-Santos","year":"2022","journal-title":"J Fungi (Basel)"},{"issue":"4","key":"pntd.0011443.ref023","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jac\/dkz529","article-title":"Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim","volume":"75","author":"W Lim","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"pntd.0011443.ref024","unstructured":"The Khartoum Call for Action, The Sixth International Conference on Mycetoma, Khartoum, Sudan, 15 February 2019 [Cited 16 May 2023]. https:\/\/cdn.who.int\/media\/docs\/default-source\/ntds\/mycetoma-chromoblastomycosis-and-other-deep-mycoses\/the-khartoum-call-for-action.pdf?sfvrsn=9c5972ae_4"},{"key":"pntd.0011443.ref025","unstructured":"WHO handbook for guideline development, second edition, Geneva, World Health Organization, 2014 [Cited 16 May 2023]. https:\/\/apps.who.int\/iris\/handle\/10665\/145714"},{"issue":"12","key":"pntd.0011443.ref026","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S1473-3099(21)00191-2","article-title":"Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology","volume":"21","author":"G Thompson","year":"2021","journal-title":"Lancet Infect Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0011443","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T17:38:24Z","timestamp":1689097104000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011443"}},"subtitle":[],"editor":[{"given":"Joshua","family":"Nosanchuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0011443","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0011443","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,28]]}}}